ES2523873T3 - Administración de un inhibidor parcial de la oxidación de ácidos grasos, tal como ranolazina, para el tratamiento de la diabetes - Google Patents

Administración de un inhibidor parcial de la oxidación de ácidos grasos, tal como ranolazina, para el tratamiento de la diabetes Download PDF

Info

Publication number
ES2523873T3
ES2523873T3 ES03755446.6T ES03755446T ES2523873T3 ES 2523873 T3 ES2523873 T3 ES 2523873T3 ES 03755446 T ES03755446 T ES 03755446T ES 2523873 T3 ES2523873 T3 ES 2523873T3
Authority
ES
Spain
Prior art keywords
diabetic
mammal
prediabetic
alkyl
level
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES03755446.6T
Other languages
English (en)
Inventor
Andrew Wolff
Markus Jerling
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Gilead Sciences Inc
Original Assignee
Gilead Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gilead Sciences Inc filed Critical Gilead Sciences Inc
Application granted granted Critical
Publication of ES2523873T3 publication Critical patent/ES2523873T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Uso de un compuesto de Fórmula I:**Fórmula** en la que: R1, R2, R3, R4 y R5 son cada uno independientemente hidrógeno, alquilo C1-4, alcoxi C1-4, ciano, trifluorometilo, halo, alquiltio C1-4, alquilsulfinilo C1-4, alquilsulfonilo C1-4 o N-alquilamido opcionalmente sustituido, siempre que cuando R1 sea metilo, R4 no sea metilo; o R2 y R3 formen juntos -OCH2O-; R6, R7, R8, R9 y R10 son cada uno independientemente hidrógeno, acilo que tiene un grupo alquilo C1-4, aminocarbonilmetilo, ciano, alquilo C1-4, alcoxi C1-4, trifluorometilo, halo, C1-4 alquitio, alquilsulfinilo C1-4, 15 alquilsulfonilo C1-4 o dialquilamino C1-4; o R6 y R7 forman juntos -CH>=CH-CH>=CH-; o R7 y R8 forman juntos -OCH2O-; R11 y R12 son cada uno independientemente hidrógeno o alquilo C1-4; y W es oxígeno o azufre; o una sal farmacéuticamente aceptable o éster del mismo, o un isómero del mismo para la preparación de una composición farmacéutica para (i) tratar la diabetes en un mamífero, (ii) reducir el nivel de HbA1c en plasma en un mamífero diabético, no diabético o prediabético, (iii) reducir el nivel de glucosa en plasma en un mamífero diabético, no diabético o prediabético, (iv) reducir el nivel total de colesterol en plasma en un mamífero diabético, no diabético o prediabético, (v) retrasar la aparición de retinopatía diabética en un mamífero diabético, no diabético o prediabético, o (vi) aumentar el nivel en plasma de colesterol de HDL en un mamífero diabético, no diabético o prediabético.

Description

imagen1
imagen2
imagen3
imagen4
imagen5
imagen6
imagen7
imagen8
imagen9
imagen10
imagen11
imagen12
imagen13
imagen14
imagen15
imagen16
imagen17
imagen18
imagen19
imagen20
imagen21
imagen22
imagen23
imagen24

Claims (1)

  1. imagen1
    imagen2
ES03755446.6T 2002-05-21 2003-05-21 Administración de un inhibidor parcial de la oxidación de ácidos grasos, tal como ranolazina, para el tratamiento de la diabetes Expired - Lifetime ES2523873T3 (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US38278102P 2002-05-21 2002-05-21
US382781P 2002-05-21
US45933203P 2003-03-31 2003-03-31
US459332P 2003-03-31
PCT/US2003/016277 WO2003099281A2 (en) 2002-05-21 2003-05-21 Administration of a partial fatty acid inhibitor such as ranolazine for the treatment of diabetes

Publications (1)

Publication Number Publication Date
ES2523873T3 true ES2523873T3 (es) 2014-12-02

Family

ID=29586970

Family Applications (1)

Application Number Title Priority Date Filing Date
ES03755446.6T Expired - Lifetime ES2523873T3 (es) 2002-05-21 2003-05-21 Administración de un inhibidor parcial de la oxidación de ácidos grasos, tal como ranolazina, para el tratamiento de la diabetes

Country Status (16)

Country Link
US (4) US20040063717A1 (es)
EP (2) EP1505977B1 (es)
JP (1) JP4546824B2 (es)
KR (1) KR101030943B1 (es)
CN (1) CN100551370C (es)
AU (1) AU2003248558B8 (es)
BR (1) BR0311161A (es)
CA (1) CA2486712C (es)
ES (1) ES2523873T3 (es)
IL (4) IL165304A0 (es)
MX (1) MXPA04011530A (es)
NO (1) NO330336B1 (es)
NZ (1) NZ536678A (es)
RU (1) RU2320343C2 (es)
WO (1) WO2003099281A2 (es)
ZA (1) ZA200409331B (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8822473B2 (en) 2002-05-21 2014-09-02 Gilead Sciences, Inc. Method of treating diabetes
AU2003248558B8 (en) 2002-05-21 2009-07-09 Gilead Sciences, Inc. Method of treating diabetes
MX2007008162A (es) * 2005-01-06 2007-07-24 Cv Therapeutics Inc Formulaciones farmaceuticas de liberacion prolongada que contienen ranolazina.
CA2678272A1 (en) * 2007-02-13 2008-10-02 Cv Therapeutics, Inc. Use of ranolazine for the treatment of cardiovascular diseases
US20090111826A1 (en) * 2007-02-13 2009-04-30 Louis Lange Use of ranolazine for the treatment of cardiovascular diseases
JP2010518171A (ja) * 2007-02-13 2010-05-27 ギリアード・パロ・アルト・インコーポレイテッド 非冠微小血管疾患の処置のためのラノラジンの使用
EP2117549A1 (en) * 2007-02-13 2009-11-18 CV Therapeutics Inc. Use of ranolazine for the treatment of coronary microvascular diseases
WO2008116083A1 (en) * 2007-03-22 2008-09-25 Cv Therapeutics, Inc. Use of ranolazine for elevated brain-type natriuretic peptide
JP2010523713A (ja) * 2007-04-12 2010-07-15 ギリアード・パロ・アルト・インコーポレイテッド インスリン分泌を増強するためのラノラジン
CA2689633A1 (en) * 2007-05-31 2008-12-11 Cv Therapeutics, Inc. Use of ranolazine for elevated brain-type natriuretic peptide
JP2010528112A (ja) * 2007-05-31 2010-08-19 ギリアード・パロ・アルト・インコーポレイテッド 糖尿病を治療する方法
RU2442585C2 (ru) * 2007-05-31 2012-02-20 Си Ви Терапьютикс, Инк. Способ лечения диабета
US20090012103A1 (en) * 2007-07-05 2009-01-08 Matthew Abelman Substituted heterocyclic compounds
BRPI0908428A2 (pt) * 2008-02-06 2015-12-08 Gilead Sciences Inc uso de ranozalina para tratar a dor.
US20110280941A1 (en) * 2008-12-11 2011-11-17 Mefford Scientific, Llc Compositions of proton pump inhibitors and insulin secretagogues, and methods of their use to treat diabetes
MX2011012140A (es) * 2009-05-14 2012-02-28 Gilead Sciences Inc Ranolazina para el tratamiento de problemas del snc.
JO3183B1 (ar) * 2010-01-29 2018-03-08 Regeneron Pharma طرق لمعالجة أمراض المناعة الذاتية مضادات dll4
TW201717919A (zh) 2015-07-02 2017-06-01 國際藥品股份公司 雷諾多重壓縮錠劑
WO2018001582A1 (en) 2016-06-30 2018-01-04 Interquim, S.A. Ranolazine multiple compressed tablets
CN110812344A (zh) * 2019-12-17 2020-02-21 卓和药业集团有限公司 一种治疗糖尿病合并心绞痛的药物组合物及制备方法
GR1010510B (el) * 2022-06-07 2023-07-20 Ελπεν Α.Ε. Φαρμακευτικη Βιομηχανια, Στερεες φαρμακοτεχνικες μορφες παρατεταμενης αποδεσμευσης ρανολαζινης

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US4173626A (en) 1978-12-11 1979-11-06 Merck & Co., Inc. Sustained release indomethacin
US4326525A (en) 1980-10-14 1982-04-27 Alza Corporation Osmotic device that improves delivery properties of agent in situ
US4567264A (en) 1983-05-18 1986-01-28 Syntex (U.S.A.) Inc. Cardioselective aryloxy- and arylthio- hydroxypropylene-piperazinyl acetanilides which affect calcium entry
US5364620A (en) 1983-12-22 1994-11-15 Elan Corporation, Plc Controlled absorption diltiazem formulation for once daily administration
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
GB2202222B (en) * 1987-03-16 1991-03-27 American Home Prod Fluorooxirane carboxylates
US5001139A (en) 1987-06-12 1991-03-19 American Cyanamid Company Enchancers for the transdermal flux of nivadipine
US4992445A (en) 1987-06-12 1991-02-12 American Cyanamid Co. Transdermal delivery of pharmaceuticals
US4902514A (en) 1988-07-21 1990-02-20 Alza Corporation Dosage form for administering nilvadipine for treating cardiovascular symptoms
ES2177601T3 (es) 1989-06-23 2002-12-16 Syntex Llc Ranolazina y pepeerazinas relacionadas para uso en el tratamiento de estados de choque. .
US5278192A (en) 1992-07-02 1994-01-11 The Research Foundation Of State University Of New York Method of vasodilator therapy for treating a patient with a condition
US5455045A (en) 1993-05-13 1995-10-03 Syntex (U.S.A.) Inc. High dose formulations
KR20010085373A (ko) * 1998-08-11 2001-09-07 노르우드 데이비드 씨. 포유류 말로닐 ＣｏＡ 데카복실라아제 억제제, 효능제 및길항제를 동정하기 위한 조성물 및 방법
US6303607B1 (en) 1998-09-10 2001-10-16 Cv Therapeutics, Inc. Method for administering a sustained release ranolanolazine formulation
US6479496B1 (en) 1998-09-10 2002-11-12 Cv Therapeutics, Inc. Methods for treating angina with ranolazine
US20050245502A1 (en) 1999-08-23 2005-11-03 Phoenix Biosciences Treatments for viral infections
US6803457B1 (en) 1999-09-30 2004-10-12 Pfizer, Inc. Compounds for the treatment of ischemia
NZ520780A (en) * 2000-02-18 2006-04-28 Cv Therapeutics Inc Partial fatty acid oxidation inhibitors in the treatment of congestive heart failure
FR2805463B1 (fr) * 2000-02-25 2003-01-24 Adir UTILISATION DE LA TRIMETAZIDINE POUR L'OBTENTION DE COMPOSITIONS PHARMACEUTIQUES DESTINEES A INHIBER L'ACYL-CoA ACETYLTRANSFERASE
US20030220312A1 (en) 2000-05-11 2003-11-27 G.D. Searle & Co. Epoxy-steroidal aldosterone antagonist and calcium channel blocker combination therapy for treatment of cardiovascular disorders
AU2001263230B2 (en) 2000-05-19 2005-03-10 Amylin Pharmaceuticals, Llc Treatment of acute coronary syndrome with glp-1
WO2002007716A2 (en) * 2000-07-21 2002-01-31 Cv Therapeutics, Inc. Method for treating angina
ATE357257T1 (de) 2000-07-27 2007-04-15 Pharmacia Corp Kombinationstherapie mit epoxy-steroidalen aldosteronantagonisten und kalziumkanalblocker zur behandlung von kongestivem herzversagen
US6423705B1 (en) 2001-01-25 2002-07-23 Pfizer Inc. Combination therapy
EP1385548B1 (en) 2001-01-26 2007-05-23 Schering Corporation Combinations of sterol absorption inhibitor(s) with cardiovascular agent(s) for the treatment of vascular conditions
MXPA04000565A (es) * 2001-07-19 2005-06-17 Cv Therapeutics Inc Compuestos de piperazina sustituidos y su uso como inhibidores de oxidacion de acidos grasos.
US20030220310A1 (en) 2001-07-27 2003-11-27 Schuh Joseph R. Epoxy-steroidal aldosterone antagonist and calcium channel blocker combination therapy for treatment of congestive heart failure
US20050250676A1 (en) 2001-11-19 2005-11-10 Aventis Pharma Deutschland Gmbh Method of activating insulin receptor substrate-2 to stimulate insulin production
US6958352B2 (en) 2002-02-08 2005-10-25 Smithkline Beecham Corporation Compounds for inhibiting insulin secretion and methods related thereto
US20080109040A1 (en) 2002-04-04 2008-05-08 Luiz Belardinelli Method of treating arrhythmias
US20030220344A1 (en) 2002-04-04 2003-11-27 Luiz Belardinelli Method of treating arrhythmias
AU2003248558B8 (en) 2002-05-21 2009-07-09 Gilead Sciences, Inc. Method of treating diabetes
US8822473B2 (en) 2002-05-21 2014-09-02 Gilead Sciences, Inc. Method of treating diabetes
WO2004079372A1 (en) 2003-03-05 2004-09-16 Metabolex Inc. Methods and compositions for treating and diagnosing diabetes and related diseases involving beta-trp
AU2004248187A1 (en) 2003-06-12 2004-12-23 University Of Colorado System Technology Systems and methods for treating human inflammatory and proliferative diseases and wounds, with fatty acid metabolism inhibitors and/or glycolytic inhibitors
US7060723B2 (en) 2003-08-29 2006-06-13 Allergan, Inc. Treating neurological disorders using selective antagonists of persistent sodium current
WO2005070126A2 (en) 2004-01-08 2005-08-04 The Regents Of The University Of Colorado Methods and compositions for treating human diseases and wounds with ucp and fas inhibitors
CA2568134A1 (en) 2004-05-24 2005-12-08 New York University Method of treating or preventing pathologic effects of acute increases in hyperglycemia and/or acute increases of free fatty acid flux
MX2007005367A (es) 2004-11-09 2007-06-18 Cv Therapeutics Inc Uso de ranolazina en combinacion con por lo menos un agente de remodelacion para revertir la remodelacion ventricular izquierda en el tratamiento de la insuficiencia cardiaca.
MX2007008162A (es) 2005-01-06 2007-07-24 Cv Therapeutics Inc Formulaciones farmaceuticas de liberacion prolongada que contienen ranolazina.
US20060205727A1 (en) 2005-03-11 2006-09-14 Wayne Kaesemeyer Combination therapy for endothelial dysfunction, angina and diabetes
US20080153840A1 (en) 2006-12-21 2008-06-26 Luiz Belardinelli Reduction of cardiovascular symptoms
CA2678272A1 (en) 2007-02-13 2008-10-02 Cv Therapeutics, Inc. Use of ranolazine for the treatment of cardiovascular diseases
EP2117549A1 (en) 2007-02-13 2009-11-18 CV Therapeutics Inc. Use of ranolazine for the treatment of coronary microvascular diseases
JP2010518171A (ja) 2007-02-13 2010-05-27 ギリアード・パロ・アルト・インコーポレイテッド 非冠微小血管疾患の処置のためのラノラジンの使用
US20090312340A1 (en) 2007-02-13 2009-12-17 Whedy Wang Use of ranolazine for the treatment of cardiovascular diseases
US20090111826A1 (en) 2007-02-13 2009-04-30 Louis Lange Use of ranolazine for the treatment of cardiovascular diseases
WO2008116083A1 (en) 2007-03-22 2008-09-25 Cv Therapeutics, Inc. Use of ranolazine for elevated brain-type natriuretic peptide
JP2010528112A (ja) 2007-05-31 2010-08-19 ギリアード・パロ・アルト・インコーポレイテッド 糖尿病を治療する方法
CA2689633A1 (en) 2007-05-31 2008-12-11 Cv Therapeutics, Inc. Use of ranolazine for elevated brain-type natriuretic peptide
BRPI0908428A2 (pt) 2008-02-06 2015-12-08 Gilead Sciences Inc uso de ranozalina para tratar a dor.
JP2012502047A (ja) 2008-09-04 2012-01-26 ギリアード サイエンシーズ， インコーポレイテッド 心房細動を治療する方法
WO2010068461A1 (en) 2008-11-25 2010-06-17 Gilead Palo Alto, Inc. Co-administration of ranolazine and cardiac glycosides
MX2011012140A (es) 2009-05-14 2012-02-28 Gilead Sciences Inc Ranolazina para el tratamiento de problemas del snc.
TWI508726B (zh) 2009-12-21 2015-11-21 Gilead Sciences Inc 治療心房纖維性顫動之方法
TW201215392A (en) 2010-06-16 2012-04-16 Gilead Sciences Inc Use of ranolazine for treating pulmonary hypertension

Also Published As

Publication number Publication date
WO2003099281A3 (en) 2004-04-01
US8883750B2 (en) 2014-11-11
WO2003099281A2 (en) 2003-12-04
IL165304A (en) 2011-08-31
US20130102555A1 (en) 2013-04-25
JP4546824B2 (ja) 2010-09-22
CN1652788A (zh) 2005-08-10
AU2003248558B8 (en) 2009-07-09
US20140378465A1 (en) 2014-12-25
NO330336B1 (no) 2011-03-28
IL165304A0 (en) 2006-01-15
ZA200409331B (en) 2005-06-29
US20040063717A1 (en) 2004-04-01
NO20045554L (no) 2004-12-20
JP2005532331A (ja) 2005-10-27
NZ536678A (en) 2007-01-26
EP1505977A2 (en) 2005-02-16
IL213809A0 (en) 2011-07-31
US20100197701A1 (en) 2010-08-05
HK1073441A1 (en) 2005-10-07
AU2003248558B2 (en) 2009-03-12
AU2003248558A1 (en) 2003-12-12
KR20040111677A (ko) 2004-12-31
EP2332540A1 (en) 2011-06-15
MXPA04011530A (es) 2005-08-15
EP1505977B1 (en) 2014-09-10
RU2320343C2 (ru) 2008-03-27
CA2486712A1 (en) 2003-12-04
KR101030943B1 (ko) 2011-04-28
US8314104B2 (en) 2012-11-20
IL213806A0 (en) 2011-07-31
RU2004133670A (ru) 2005-06-10
BR0311161A (pt) 2005-03-29
CN100551370C (zh) 2009-10-21
CA2486712C (en) 2012-01-03

Similar Documents

Publication Publication Date Title
ES2500068T3 (es) Inhibidores heterocíclicos de MEK y métodos de uso de los mismos
RU2004133670A (ru) Способ лечения диабета
AR025276A1 (es) El uso de un compuesto que es un derivado de 2-amino-1,3-tiazol, un compuesto que es un derivado de 2-amino-1,3-tiazol, un procedimiento para producirlo y una composicion farmaceutica que lo comprende
RU2008136198A (ru) Полимерные композиции ингибиторов сетр
KR950016745A (ko) 생리증상의 치료방법 및 이를 위한 조성물
PE20001485A1 (es) Derivados de la camptotecina que tienen actividad antitumoral
KR930700490A (ko) 탄산탈수효소 억제제로서 유용한 티오펜 설폰아미드
RU2009112207A (ru) Конкретное глюкокортикостероидное соединение, обладающее противовоспалительной активностью
KR890701557A (ko) 리폭시게나제 억제화합물을 함유하는 푸란 및 피롤
BRPI0407506A (pt) compostos para o tratamento de distúrbios metabólicos, seu uso e composição farmacêutica compreendendo os mesmos
JP2005532331A5 (es)
AR020016A2 (es) Compuestos derivados de la eritromicina, composiciones que los contienen, uso de los mismos para preparar un medicamento
UY27533A1 (es) Composiciones farmacéuticas que contienen oxibutinina
IS4218A (is) Hliðstæð aðferð við að framleiða skammvirk tvíhýdrópýridín
RU2333209C2 (ru) Композиции и способы для борьбы с дисфункциями нижних мочевых путей с использованием агонистов дельта-опиоидных рецепторов
ATE507212T1 (de) Morpholine als 5ht2c-agonisten
PE20010541A1 (es) Uso de una composicion de benzimidazol para tratar el cancer
EA200200831A1 (ru) Фармацевтическая композиция, включающая пеметрексед вместе с монотиоглицерином, l-цистеином или тиогликолевой кислотой
de Vicente et al. Non-nucleoside inhibitors of HCV polymerase NS5B. Part 2: Synthesis and structure–activity relationships of benzothiazine-substituted quinolinediones
RU2004101229A (ru) Дейтерированные n-и альфа-замещенные аминоалкилэфиры дифенилакоксиуксуной кислоты, а также лекарственные средства, содержащие эти соединения
AR063894A1 (es) Uso de un acido indazolmetoxialcanoico para preparar una composicion farmaceutica
PE20021018A1 (es) DERIVADOS DE ß - CARBOLINA
AR056321A1 (es) COMBINACIONES TERAPÉUTICAS PARA EL TRATAMIENTO O LA PREVENCIoN DE TRASTORNOS PSICoTICOS
KR890009867A (ko) 비 펩타이드성 레닌 억제제
AR036351A1 (es) Isoxazolopiridinonas, el uso de las mismas para la fabricacion de un medicamento, composiciones y combinaciones farmaceuticas